We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$887M
AUM Growth
+$16.2M
Cap. Flow
+$129M
Cap. Flow %
14.54%
Top 10 Hldgs %
50.79%
Holding
136
New
23
Increased
31
Reduced
31
Closed
36

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$44.9M
2
MRK icon
Merck
MRK
+$22.8M
3
GSK icon
GSK
GSK
+$21.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.53M
5
V icon
Visa
V
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 60.28%
2 Technology 12.21%
3 Industrials 2.92%
4 Consumer Discretionary 0.53%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WAB icon
126
Wabtec
WAB
$49.1B
-53,114
Closed -$5.57M
ZYME icon
127
Zymeworks
ZYME
$1.61B
-73,800
Closed -$1.16M
MRTX
128
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
-112,908
Closed -$5.32M
OBSV
129
DELISTED
ObsEva SA Ordinary Shares
OBSV
-243,669
Closed -$4.39M
TMX
130
DELISTED
Terminix Global Holdings, Inc.
TMX
-14,184
Closed -$395K
EIDX
131
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
-31,522
Closed -$315K
CISN
132
DELISTED
Cision Ltd. Ordinary Share
CISN
-15,000
Closed -$252K
BOLD
133
DELISTED
Audentes Therapeutics, Inc
BOLD
-120,000
Closed -$4.75M
ULTI
134
DELISTED
Ultimate Software Group Inc
ULTI
-800
Closed -$258K

Similar funds

Sphera Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sphera Funds Management held 136 positions worth $887M, up 1.9% from $871M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management deployed $129M of net new capital in Q4 2018, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was Celgene Corp: 465,000 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 75% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $22.8M trimmed.

  • Sphera Funds Management's largest Q4 2018 buy was Celgene Corp: 465,000 shares worth $29.8M.
  • Sphera Funds Management added most to Viatris in Q4 2018, an estimated $11.4M increase.
  • Sphera Funds Management's biggest Q4 2018 reduction was Merck, cutting an estimated $22.8M.
  • Sphera Funds Management fully exited Johnson & Johnson in Q4 2018, selling an estimated $44.9M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $887M portfolio in Q4 2018.
  • Sphera Funds Management opened 23 new positions and closed 36 in Q4 2018.
  • Sphera Funds Management's portfolio value rose 1.9% quarter-over-quarter to $887M.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.